cyproheptadine has been researched along with Rhinitis, Allergic, Perennial in 25 studies
Cyproheptadine: A serotonin antagonist and a histamine H1 blocker used as antipruritic, appetite stimulant, antiallergic, and for the post-gastrectomy dumping syndrome, etc.
cyproheptadine : The product resulting from the formal oxidative coupling of position 5 of 5H-dibenzo[a,d]cycloheptene with position 4 of 1-methylpiperidine resulting in the formation of a double bond between the two fragments. It is a sedating antihistamine with antimuscarinic and calcium-channel blocking actions. It is used (particularly as the hydrochloride sesquihydrate) for the relief of allergic conditions including rhinitis, conjunctivitis due to inhalant allergens and foods, urticaria and angioedema, and in pruritic skin disorders. Unlike other antihistamines, it is also a seratonin receptor antagonist, making it useful in conditions such as vascular headache and anorexia.
Rhinitis, Allergic, Perennial: Inflammation of the mucous membrane of the nose similar to that found in hay fever except that symptoms persist throughout the year. The causes are usually air-borne allergens, particularly dusts, feathers, molds, animal fur, etc.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To measure the reduction in nasal obstruction using acoustic rhinometry in patients with allergic rhinitis treated with rupatadine." | 5.14 | Reduction of nasal volume after allergen-induced rhinitis in patients treated with rupatadine: a randomized, cross-over, double-blind, placebo-controlled study. ( Bartrá, J; Izquierdo, I; Mullol, J; Muñoz-Cano, R; Picado, C; Serrano, C; Valero, A, 2009) |
| " Rupatadine, a molecule with intense antihistaminic activity and with antagonist PAF effects through its interaction with specific receptors, is indicated for the treatment of intermittent or persistent allergic rhinitis and urticaria." | 4.89 | Efficacy and safety of rupatadine for allergic rhino-conjunctivitis: a systematic review of randomized, double-blind, placebo-controlled studies with meta-analysis. ( Canonica, GW; Compalati, E, 2013) |
| "The second-generation H1-receptor antagonists terfenadine, astemizole, loratadine, and cetirizine are important first-line drugs for the relief of symptoms in patients with allergic rhinoconjunctivitis or chronic urticaria and may eventually supplant the potentially sedating first-generation H1-receptor antagonists in the treatment of these disorders." | 4.78 | Recent advances in H1-receptor antagonist treatment. ( Simons, FE, 1990) |
| "Rupatadine (Rupafin), a novel antihistamine approved recently in Europe for the treatment of allergic rhinitis (AR) and chronic idiopathic urticaria in patients aged>or=12 years, has been shown to be highly efficacious, and as safe and well tolerated as other commonly employed antihistamines in the treatment of allergic disease." | 2.74 | Safety of rupatadine administered over a period of 1 year in the treatment of persistent allergic rhinitis: a multicentre, open-label study in Spain. ( Antépara, I; Borja, J; Castillo, JA; de la Torre, F; del Cuvillo, A; Donado, E; Izquierdo, I; Molà, O; Rivas, P; Valero, A, 2009) |
| "Loratadine was administered in a single daily dose of 5 mg (2." | 2.67 | [Loratadine and dexchlorpheniramine in the treatment of perennial allergic rhinitis in pediatric patients]. ( Longo, G; Marchesi, E; Poli, F; Ventura, A, 1990) |
| "Loratadine was safe and well tolerated and was significantly less sedative than clemastine; loratadine may therefore possess an advantage in clinical use in the treatment of perennial allergic rhinitis." | 2.67 | A multicentre study of loratadine, clemastine and placebo in patients with perennial allergic rhinitis. ( Etholm, B; Frølund, L; Irander, K; Johannessen, TA; Odkvist, L; Ohlander, B; Weeke, B, 1990) |
| "Two patient groups were treated, one with seasonal allergic rhinitis for two days during the peak of the ragweed season, and another with perennial allergic rhinitis for an extended six-week period." | 2.65 | Controlled comparison of anew antihistamine-decongestant combination to its individual components. ( Falliers, CJ; Redding, MA, 1980) |
| "1 The efficacy of the antihistamine azatadine maleate at maximum recommended dosage (4 mg/day) for 1 week was assessed relative to placebo in a double-blind crossover study of twenty patients with perennial allergic rhinitis." | 2.65 | Azatadine maleate in perennial allergic rhinitis: effects on clinical symptoms and choice reaction time. ( Aman, MG; Hillas, JL; Somerfield, SD; Wilson, JD, 1980) |
| " Eighty percent of patients had symptomatic relief with a twice daily dosage of 2 mg." | 2.65 | Azatadine maleate (Zadine): evaluation in the management of allergic rhinitis. ( Hillas, JL; Somerfield, SD; Wilson, JD, 1981) |
| "Rupatadine is a once-daily non-sedative, selective, long-acting H1 anti-histamine with antagonistic PAF effects through its interaction with specific receptors." | 2.45 | Pharmacological profile, efficacy and safety of rupatadine in allergic rhinitis. ( Katiyar, S; Prakash, S, 2009) |
| "Rupatadine is a once-daily, non-sedating, selective and long-acting new drug with a strong antagonist activity towards both histamine H(1) receptors and platelet-activating factor receptors." | 2.43 | Rupatadine: pharmacological profile and its use in the treatment of allergic disorders. ( Picado, C, 2006) |
| "Rupatadine is a new agent for the management of diseases with allergic inflammatory conditions, such as seasonal and perennial rhinitis." | 2.42 | Rupatadine: a new selective histamine H1 receptor and platelet-activating factor (PAF) antagonist. A review of pharmacological profile and clinical management of allergic rhinitis. ( García-Rafanell, J; Izquierdo, I; Merlos, M, 2003) |
| "Loratadine is a long acting antihistamine which has a high selectivity for peripheral histamine H1-receptors and lacks the central nervous system depressant effects often associated with some of the older antihistamines." | 2.38 | Loratadine. A preliminary review of its pharmacodynamic properties and therapeutic efficacy. ( Clissold, SP; Goa, KL; Sorkin, EM, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (28.00) | 18.7374 |
| 1990's | 4 (16.00) | 18.2507 |
| 2000's | 8 (32.00) | 29.6817 |
| 2010's | 6 (24.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Compalati, E | 2 |
| Canonica, GW | 3 |
| Berger, VW | 1 |
| Gudehithlu, SK | 1 |
| Braido, F | 1 |
| Sclifò, F | 1 |
| Ferrando, M | 1 |
| Fantin, S | 1 |
| Maspero, J | 1 |
| Bisbal, C | 1 |
| Agache, I | 1 |
| Donado, E | 2 |
| Borja, J | 2 |
| Mola, O | 2 |
| Izquierdo, I | 5 |
| Katiyar, S | 1 |
| Prakash, S | 1 |
| Valero, A | 2 |
| de la Torre, F | 1 |
| Castillo, JA | 1 |
| Rivas, P | 1 |
| del Cuvillo, A | 1 |
| Antépara, I | 1 |
| Serrano, C | 1 |
| Bartrá, J | 1 |
| Muñoz-Cano, R | 1 |
| Mullol, J | 2 |
| Picado, C | 3 |
| Metz, M | 1 |
| Maurer, M | 2 |
| Potter, P | 1 |
| Maspero, JF | 1 |
| Vermeulen, J | 1 |
| Barkai, L | 1 |
| Németh, I | 1 |
| Baillieau, RA | 1 |
| Garde, JM | 1 |
| Giralt, J | 1 |
| Doménech, A | 1 |
| Nieto, A | 1 |
| Merlos, M | 1 |
| García-Rafanell, J | 1 |
| Keam, SJ | 1 |
| Plosker, GL | 1 |
| Bousquet, J | 1 |
| Bachert, C | 1 |
| Canonica, WG | 1 |
| Gimenez-Arnau, A | 1 |
| Kowalski, ML | 1 |
| Martí-Guadaño, E | 1 |
| Scadding, G | 1 |
| Van Cauwenberge, P | 1 |
| Falliers, CJ | 1 |
| Redding, MA | 1 |
| Hillas, JL | 2 |
| Somerfield, SD | 2 |
| Wilson, JD | 2 |
| Aman, MG | 1 |
| Simons, FE | 3 |
| Lukowski, JL | 1 |
| Becker, AB | 1 |
| Simons, KJ | 1 |
| Longo, G | 1 |
| Poli, F | 1 |
| Ventura, A | 1 |
| Marchesi, E | 1 |
| Frølund, L | 1 |
| Etholm, B | 1 |
| Irander, K | 1 |
| Johannessen, TA | 1 |
| Odkvist, L | 1 |
| Ohlander, B | 1 |
| Weeke, B | 1 |
| Clissold, SP | 1 |
| Sorkin, EM | 1 |
| Goa, KL | 1 |
| Bruttmann, G | 1 |
| Charpin, D | 1 |
| Germouty, J | 1 |
| Horak, F | 1 |
| Kunkel, G | 1 |
| Wittmann, G | 1 |
| Togias, A | 1 |
| Proud, D | 1 |
| Kagey-Sobotka, A | 1 |
| Norman, P | 1 |
| Lichtenstein, L | 1 |
| Naclerio, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Nasal Ocular Reflexes Contribute to Eye Symptoms in Patients With Allergic Rhinitis[NCT00117832] | 20 participants | Interventional | 2005-03-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
10 reviews available for cyproheptadine and Rhinitis, Allergic, Perennial
| Article | Year |
|---|---|
Efficacy and safety of rupatadine for allergic rhino-conjunctivitis: a systematic review of randomized, double-blind, placebo-controlled studies with meta-analysis.
Topics: Conjunctivitis, Allergic; Cyproheptadine; Histamine Antagonists; Humans; Platelet Activating Factor; | 2013 |
New therapies for allergic rhinitis.
Topics: Administration, Intranasal; Androstadienes; Anti-Allergic Agents; Antibodies, Anti-Idiotypic; Antibo | 2014 |
Pharmacological profile, efficacy and safety of rupatadine in allergic rhinitis.
Topics: Adolescent; Adult; Cyproheptadine; Histamine H1 Antagonists, Non-Sedating; Humans; Randomized Contro | 2009 |
Rupatadine for the treatment of allergic rhinitis and urticaria.
Topics: Anti-Allergic Agents; Chronic Disease; Cyproheptadine; Histamine H1 Antagonists; Humans; Platelet Ac | 2011 |
Rupatadine: a new selective histamine H1 receptor and platelet-activating factor (PAF) antagonist. A review of pharmacological profile and clinical management of allergic rhinitis.
Topics: Animals; Clinical Trials as Topic; Cyproheptadine; Dose-Response Relationship, Drug; Histamine H1 An | 2003 |
Rupatadine: pharmacological profile and its use in the treatment of allergic disorders.
Topics: Adolescent; Adult; Animals; Cyproheptadine; Histamine H1 Antagonists; Humans; Psychomotor Performanc | 2006 |
Rupatadine: a review of its use in the management of allergic disorders.
Topics: Adolescent; Adult; Aged; Animals; Anti-Allergic Agents; Cyproheptadine; Drug Interactions; Humans; H | 2007 |
Rupatadine in allergic rhinitis and chronic urticaria.
Topics: Adolescent; Animals; Anti-Allergic Agents; Child; Chronic Disease; Clinical Trials as Topic; Cyprohe | 2008 |
Recent advances in H1-receptor antagonist treatment.
Topics: Astemizole; Benzhydryl Compounds; Benzimidazoles; Cetirizine; Cyproheptadine; Histamine H1 Antagonis | 1990 |
Loratadine. A preliminary review of its pharmacodynamic properties and therapeutic efficacy.
Topics: Animals; Common Cold; Cyproheptadine; Female; Humans; Loratadine; Male; Rhinitis, Allergic, Perennia | 1989 |
12 trials available for cyproheptadine and Rhinitis, Allergic, Perennial
| Article | Year |
|---|---|
A 12-week placebo-controlled study of rupatadine 10 mg once daily compared with cetirizine 10 mg once daily, in the treatment of persistent allergic rhinitis.
Topics: Adolescent; Adult; Anti-Allergic Agents; Cetirizine; Cyproheptadine; Double-Blind Method; Female; Hu | 2008 |
Safety of rupatadine administered over a period of 1 year in the treatment of persistent allergic rhinitis: a multicentre, open-label study in Spain.
Topics: Adolescent; Adult; Aged; Child; Cyproheptadine; Electrocardiography; Female; Follow-Up Studies; Hist | 2009 |
Reduction of nasal volume after allergen-induced rhinitis in patients treated with rupatadine: a randomized, cross-over, double-blind, placebo-controlled study.
Topics: Administration, Intranasal; Adolescent; Adult; Anti-Allergic Agents; Cyproheptadine; Disease Progres | 2009 |
Rupatadine oral solution in children with persistent allergic rhinitis: A randomized, double-blind, placebo-controlled study.
Topics: Administration, Oral; Analysis of Variance; Anti-Allergic Agents; Argentina; Child; Cyproheptadine; | 2013 |
Controlled comparison of anew antihistamine-decongestant combination to its individual components.
Topics: Cyproheptadine; Drug Therapy, Combination; Ephedrine; Female; Histamine H1 Antagonists; Humans; Male | 1980 |
Azatadine maleate in perennial allergic rhinitis: effects on clinical symptoms and choice reaction time.
Topics: Adolescent; Adult; Clinical Trials as Topic; Cyproheptadine; Female; Histamine Antagonists; Humans; | 1980 |
Azatadine maleate (Zadine): evaluation in the management of allergic rhinitis.
Topics: Adolescent; Adult; Child; Clinical Trials as Topic; Cyproheptadine; Double-Blind Method; Female; Hum | 1981 |
Comparison of the effects of single doses of the new H1-receptor antagonists loratadine and terfenadine versus placebo in children.
Topics: Benzhydryl Compounds; Child; Cyproheptadine; Female; Histamine H1 Antagonists; Humans; Loratadine; M | 1991 |
[Loratadine and dexchlorpheniramine in the treatment of perennial allergic rhinitis in pediatric patients].
Topics: Age Factors; Child; Child, Preschool; Chlorpheniramine; Cyproheptadine; Female; Histamine Antagonist | 1990 |
A multicentre study of loratadine, clemastine and placebo in patients with perennial allergic rhinitis.
Topics: Adolescent; Adult; Aged; Clemastine; Cyproheptadine; Double-Blind Method; Female; Histamine Antagoni | 1990 |
Evaluation of the efficacy and safety of loratadine in perennial allergic rhinitis.
Topics: Adolescent; Adult; Benzhydryl Compounds; Child; Cyproheptadine; Double-Blind Method; Female; Histami | 1989 |
The effect of a topical tricyclic antihistamine on the response of the nasal mucosa to challenge with cold, dry air and histamine.
Topics: Administration, Topical; Adult; Cold Temperature; Cyproheptadine; Female; Histamine; Humans; Humidit | 1987 |
3 other studies available for cyproheptadine and Rhinitis, Allergic, Perennial